111 related articles for article (PubMed ID: 18179662)
1. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.
Davies LM; Barnes TR; Jones PB; Lewis S; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
Value Health; 2008; 11(4):549-62. PubMed ID: 18179662
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of clozapine therapy for severe psychosis.
Ghaemi SN; Ziegler DM; Peachey TJ; Goodwin FK
Psychiatr Serv; 1998 Jun; 49(6):829-31. PubMed ID: 9634167
[TBL] [Abstract][Full Text] [Related]
5. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.
Rosenheck RA; Leslie DL; Sindelar JL; Miller EA; Tariot PN; Dagerman KS; Davis SM; Lebowitz BD; Rabins P; Hsiao JK; Lieberman JA; Schneider LS;
Arch Gen Psychiatry; 2007 Nov; 64(11):1259-68. PubMed ID: 17984395
[TBL] [Abstract][Full Text] [Related]
6. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of atypicals in the UK.
Heeg B; Buskens E; Botteman M; Caleo S; Ingham M; Damen J; de Charro F; van Hout B
Value Health; 2008 Dec; 11(7):1007-21. PubMed ID: 18489517
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
Foussias G; Remington G
Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.
Essock SM; Frisman LK; Covell NH; Hargreaves WA
Arch Gen Psychiatry; 2000 Oct; 57(10):987-94. PubMed ID: 11015817
[TBL] [Abstract][Full Text] [Related]
11. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec.
Latimer E; Wynant W; Clark R; Malla A; Moodie E; Tamblyn R; Naidu A
Clin Schizophr Relat Psychoses; 2013 Apr; 7(1):33-41. PubMed ID: 23367500
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
15. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
[TBL] [Abstract][Full Text] [Related]
16. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends.
Luchins DJ; Hanrahan P; Shinderman M; Lagios L; Fichtner CG
Psychiatr Serv; 1998 Aug; 49(8):1034-8. PubMed ID: 9712208
[TBL] [Abstract][Full Text] [Related]
17. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.
Duggan A; Warner J; Knapp M; Kerwin R
Br J Psychiatry; 2003 Jun; 182():505-8. PubMed ID: 12777341
[TBL] [Abstract][Full Text] [Related]
18. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model.
Jin H; Tappenden P; MacCabe JH; Robinson S; Byford S
JAMA Netw Open; 2020 May; 3(5):e205888. PubMed ID: 32459356
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
Davies LM; Lewis S; Jones PB; Barnes TR; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
Br J Psychiatry; 2007 Jul; 191():14-22. PubMed ID: 17602120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
